ClinicalTrials.gg
CompletedNCT05864365Updated Apr 1, 2025

A Biomarker Study of ATH434 in Participants With MSA

A Phase 2 interventional study of ATH434 in Multiple System Atrophy, sponsored by Alterity Therapeutics. Completed at 1 site in United States. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by Alterity Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies in Multiple System Atrophy with a site in United States — 21 open to participants now, 32 under way, 1 of them phase 3. Multiple System Atrophy · United States.

Enrollment
47th of 57
10 · median 35
Started
2023
with 4 others
Phase 2
17 of 90
2 open now
Registered
72nd of 90
by date
Lead sponsor
2 of 90
Alterity Therapeutics

Among the 90 studies in Multiple System Atrophy with a site in United States, this one is the 47th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2023, is one of 17 in phase 2, and was the 72nd registered.

Multiple System Atrophy

207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.

Browse Multiple System Atrophy studies →

Open to participants now

21 of the 90 studies in Multiple System Atrophy with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 18 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Multiple System Atrophy with a site in United States, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy

03

Conditions studied

  • Multiple System Atrophy

Keywords

  • Multiple System Atrophy
  • ATH434
  • Neurodegenerative disease
  • Shy-Drager Syndrome
  • Movement disorders
  • Autonomic dysfunction
  • Synucleinopathies
  • Atypical parkinsonism
  • Biomarkers
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has clinical features of parkinsonism.
  2. Participant has evidence of orthostatic hypotension and/or bladder dysfunction.
  3. Participant has ataxia and/or pyramidal signs on neurological examination.
  4. Participant has biomarker evidence of MSA in biologic fluid and on MRI.

Exclusion criteria

Exclusion Criteria:

  1. Participant is unable to swallow study drug.
  2. Participant is unable to attend study visits or complete study procedures.
  3. Participant has structural brain abnormality on MRI.
  4. Participant has any significant neurological disorder other than MSA.
  5. Participant has an unstable medical or psychiatric illness.
  6. Participant has a to, or is unable to tolerate, MRI or lumbar puncture.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    ATH434

    Drug: ATH434

Interventions

  • DrugATH434

    ATH434 taken by mouth two times per day

06

What researchers measure

Primary outcomes

  1. Change in brain volume as measured by MRI

    Time frame: Change from Baseline to Week 52

Secondary outcomes

  1. Change in iron content in substantia nigra as measured by MRI

    Time frame: Change from Baseline to Week 52

  2. Change in Unified MSA Rating Scale (UMSARS) Score

    Time frame: Change from Baseline to Week 52

  3. Change in Patient Global Impression of Change (PGI-C)

    Time frame: Change from Baseline to Week 52

  4. Change in Clinical Global Impression of Change (CGI-C)

    Time frame: Change from Baseline to Week 52

  5. Change in Neurofilament Light Chain Levels

    Time frame: Change from Baseline to Week 52

07

Study locations

1 site
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Feb 2025, 21 months.

Of 19 phase 2 interventional studies under Multiple System Atrophy, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 32. This study's 21 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2023
First posted
May 18, 2023
StartActual
May 23, 2023
Primary completionActual
Feb 26, 2025
CompletionActual
Feb 26, 2025
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05864365
Lead sponsor
Alterity Therapeutics
Responsible party
Sponsor
First posted
May 18, 2023
Start date
May 23, 2023
Primary completion
Feb 26, 2025
Completion
Feb 26, 2025
Last update
Apr 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ATH434

Start the discussion